Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone.

[1]  R. Jenkins.  The fourth wave of the US opioid epidemic and its implications for the rural US: A federal perspective. , 2021, Preventive medicine.

[2]  Udi E. Ghitza,et al.  Bupropion and Naltrexone in Methamphetamine Use Disorder. , 2021, The New England journal of medicine.

[3]  J. Stephenson.  CDC Warns of Surge in Drug Overdose Deaths During COVID-19. , 2021, JAMA health forum.

[4]  C. Banta-Green,et al.  Interest in reducing methamphetamine and opioid use among syringe services program participants in Washington State. , 2020, Drug and alcohol dependence.

[5]  T. Cicero,et al.  Polysubstance Use: A Broader Understanding of Substance Use During the Opioid Crisis. , 2019, American journal of public health.

[6]  E. Vittinghoff,et al.  Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial. , 2019, JAMA psychiatry.

[7]  B. Leroux,et al.  Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. , 2019, Journal of substance abuse treatment.

[8]  J. Duchin,et al.  Engaging an Unstably Housed Population with Low-Barrier Buprenorphine Treatment at a Syringe Services Program: Lessons Learned from Seattle, Washington , 2019, Substance abuse.

[9]  R. Lechtenberg,et al.  Outbreak of Human Immunodeficiency Virus Infection Among Heterosexual Persons Who Are Living Homeless and Inject Drugs — Seattle, Washington, 2018 , 2019, MMWR. Morbidity and mortality weekly report.

[10]  T. Cicero,et al.  Twin epidemics: The surging rise of methamphetamine use in chronic opioid users. , 2018, Drug and alcohol dependence.

[11]  E. Nunes,et al.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial , 2017, The Lancet.

[12]  M. Golden,et al.  Increasing methamphetamine injection among non-MSM who inject drugs in King County, Washington. , 2018, Drug and alcohol dependence.

[13]  J. Merrill,et al.  Linking patients with buprenorphine treatment in primary care: Predictors of engagement. , 2017, Drug and alcohol dependence.

[14]  Lisa Raville,et al.  Heroin and Methamphetamine Injection: An Emerging Drug Use Pattern , 2017, Substance use & misuse.

[15]  W. Ling,et al.  Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. , 2016, Addiction.

[16]  J. Tiihonen,et al.  Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. , 2012, The American journal of psychiatry.

[17]  N. Petry.  Contingency management treatments: controversies and challenges. , 2010, Addiction.